Reduction of Diabetic Macular Edema by Oral Administration of the Kinase Inhibitor PKC412
The DOI matches its Crossref record.
Abstract
PURPOSE: To evaluate the efficacy and safety of PKC412, an orally administered kinase inhibitor, in subjects with diabetic macular edema. METHODS: This was a randomized (1:1:1:1), multicenter, double-masked, parallel-group study in which subjects (n = 141) received placebo or PKC412 (50, 100, or 150 mg/d) for up to 3 months. Subjects were 18 to 85 years of age and had retinal thickening that met predefined criteria and best corrected visual acuity of 55 letters or more. Efficacy was based on changes in retinal thickening measured by grading of fundus photographs and optical coherence tomography (OCT) and changes in visual acuity. RESULTS: Grading of fundus photographs showed a statistically significant decrease in the area of greatest retinal thickening in patients receiving 150 mg/d of PKC412 (P = 0.032). OCT demonstrated that the two higher doses of PKC412 caused a significant decrease in thickening in the region of greatest thickening and in the fovea (P < or = 039), with response in the high-dose group significantly different from that in the placebo group (difference = -66.69 micro m [95.2% CI: -128.57 to -4.81]; P = 0.030). Retinal volume for all locations also showed a significant decrease from baseline in the 100- and 150-mg/d PKC412 groups (P < or = 004), and the 150-mg/kg group showed significantly less retinal volume than the placebo group at 3 months (difference = -0.46 mm(3) [95.2% CI: -0.86-0.06]; P = 0.019). There was a small (4.36 letters), but significant (P = 0.007), improvement in visual acuity at 3 months compared with baseline in the 100-mg/d PKC412 group. Gastrointestinal side effects (diarrhea, nausea, and vomiting) were the most common adverse events attributed to the drug. Dose-related effects were observed for tolerability, glycemic control, and liver toxicity. CONCLUSIONS: Orally administered PKC412 at doses of 100 mg/d or higher may significantly reduce macular edema and improve visual acuity in diabetic subjects. However, concern regarding liver toxicity with systemic therapy makes local delivery an appealing approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563
Optical coherence tomography: a review of clinical development from bench to bedside
Zysk, A. M., Nguyen, F. T., Oldenburg, A. L., Marks, D. L., & Boppart, S. A. (2007) · Journal of Biomedical Optics · doi:10.1117/1.2793736 · Cited by 547
Molecular pathogenesis of retinal and choroidal vascular diseases
Campochiaro, P. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.002 · Cited by 545
Self-citationThe role of protein kinase C activation and the vascular complications of diabetes
DASEVCIMEN, N., & KING, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.016 · Cited by 494
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity
Sánchez, C., Méndez, C., & Salas, J. A. (2006) · Nat. Prod. Rep. · doi:10.1039/b601930g · Cited by 407
Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema
Nguyen, Q. D., Tatlipinar, S., Shah, S. M., Haller, J. A., Quinlan, E., Sung, J., Zimmer-Galler, I., Do, D. V., & Campochiaro, P. A. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.06.068 · Cited by 351
Self-citationNguyen, Q. D., Shah, S. M., Heier, J. S., Do, D. V., Lim, J., Boyer, D., Abraham, P., & Campochiaro, P. A. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.023 · Cited by 340
Self-citationPrimary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema
Arevalo, J. F., Fromow-Guerra, J., Quiroz-Mercado, H., Sanchez, J. G., Wu, L., Maia, M., Berrocal, M. H., Solis-Vivanco, A., & Farah, M. E. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.12.028 · Cited by 335
Gupta, N., Mansoor, S., Sharma, A., Sapkal, A., Sheth, J., Falatoonzadeh, P., Kuppermann, B., & Kenney, M. (2013) · The Open Ophthalmology Journal · doi:10.2174/1874364101307010004 · Cited by 285
Effect of Ruboxistaurin on Visual Loss in Patients with Diabetic Retinopathy
(2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.07.032 · Cited by 276
Noma, H., Minamoto, A., Funatsu, H., Tsukamoto, H., Nakano, K., Yamashita, H., & Mishima, H. K. (2006) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-004-1087-4 · Cited by 274
Kollias, A. N., & Ulbig, M. W. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0075 · Cited by 253
Reactive oxygen species: sources, consequences and targeted therapy in type 2 diabetes
Panigrahy, S. K., Bhatt, R., & Kumar, A. (2017) · Journal of Drug Targeting · doi:10.1080/1061186x.2016.1207650 · Cited by 103
Vinores, S. A., Xiao, W., Aslam, S., Shen, J., Oshima, Y., Nambu, H., Liu, H., Carmeliet, P., & Campochiaro, P. A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20525 · Cited by 99
Self-citationMicrovascular complications and diabetic retinopathy: recent advances and future implications
Barot, M., Gokulgandhi, M. R., Patel, S., & Mitra, A. K. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.206 · Cited by 92
Metadata
- Authors
- Campochiaro, P. A.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2004-03-01
- Volume
- 45
- Issue
- 3
- Pages
- 922
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2084691395
- Cited by
- 141
- References
- 0
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.